Illumina Says Clinical Sequencing Demand Drove Q3 2026 Earnings Beat
Illumina management attributed the company’s Q3 2026 earnings beat to clinical sequencing demand.
Related stories
Cann Group Posts Q1 Revenue of A$3.45 Million
M impact | EQUITY | Oct 30, 2026, 12:57 AM UTC
Civmec shares rise on upbeat quarterly results
Civmec shares rose on upbeat quarterly results.
M impact | EQUITY | Oct 30, 2026, 12:55 AM UTC
Hyundai Mobis Q3 Operating Profit Rises 17.15% Year on Year
M impact | EQUITY | Oct 30, 2026, 12:54 AM UTC
Firstwave Cloud Technology Reports Quarterly Revenue of A$1.90M
M impact | EQUITY | Oct 30, 2026, 12:54 AM UTC
Amazon Shares Fall 7% After Q3 Results Show Weaker Free Cash Flow
Amazon shares fell more than 7% in extended trading after third-quarter results missed expectations, fourth-quarter revenue guidance midpoint trailed projections and free cash flow
M impact | EQUITY | Oct 30, 2026, 12:51 AM UTC
Japan's Nikkei average falls 2%
M impact | EQUITY | Oct 30, 2026, 12:50 AM UTC